PAK4 and cancer: In addition, PAK4 lies downstream of EGFR in the ERBB signaling pathway; hence, the nine FDA-approved cancer drugs targeting EGFR should be assessed to see if they ameliorate the effects of PAK4 mutations and could be used to treat HGSOC patients.